Key Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MorePatients infected with Leishmania braziliensis develop chronic lesions that often fail to respond to treatment. To determine whether genes whose expression is highly variable in lesions might influence disease outcome, we obtained biopsies of lesions from patients prior to drug treatment, performed transcriptomic profiling, and identified highly variable genes whose expression correlated with treatment outcome. Amongst the most variable genes were components of the cytolytic pathway, the expression of which appeared to be driven by parasite load in the skin. We demonstrated that treatment failure can be directly linked to the cytolytic pathway activated during infection. Using this host-pathogen biomarker profile, we show that treatment outcome can be predicted before the start of treatment. These findings not only raise the possibility of point-of-care diagnostic screening to identify patients at high risk of treatment failure and provide a rationale for a precision medicine approach to drug selection in cutaneous leishmaniasis, but more broadly also demonstrate the value of identifying genes of high variability in other diseases to better understand and predict diverse clinical outcomes. SOURCE: daniel beiting (beiting@vet.upenn.edu) - Beiting University of Pennsylvania
View on GEOView in PlutoEnhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreUse Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView quality control data and experiment metadata for this experiment.
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team